Delivery Order HHSD200200824959I-HHSD2002008249590009
Award Date
9/30/16
Potential Completion Date
8/31/18
Potential Value
$38M
Federal Agency
CDC Pittsburgh
Ultimate Awardee
Not listed
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Cambridge, MA 02139, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $99,941,719.80 definitive, firm fixed-price contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Emergent Biodefense Operations Lansing LLC, doing business as Emergent Biodefense, on March 16, 2017. The contract has an ultimate completion date of March 15, 2019 and is not set aside. Emergent Biodefense is a for-profit manufacturer of medical countermeasures and biopharmaceuticals, specializing in vaccines and therapeutics for public health...
The U.S. Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $41,801,810.00 firm fixed-price delivery order contract to Emergent Biodefense Operations Lansing LLC, doing business as Emergent Biodefense, for the procurement of BioThrax (Anthrax Vaccine Adsorbed). This contract, which is not a set-aside, has an ultimate completion date of September 30, 2025. Emergent Biodefense is the prime contractor and manufacturer of BioThrax, the only...
<p>This is a contract awarded by the Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) to Emergent Biodefense Operations Lansing LLC, also known as Emergent Biodefense, for the maintenance of a smallpox license. The contract is a delivery order with a firm fixed price of $38,430,000.00 and a completion date of January 31, 2019. The place of performance is located in Cambridge, Massachusetts. The contract does not have a set-aside designation.</p>
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a Firm Fixed Price Purchase Order contract to Emergent Biodefense Operations Lansing LLC for vaccine potency testing services. The $127,526.00 contract has a completion date of November 30, 2018 and was awarded on August 31, 2018. The place of performance is Lansing, Michigan. Emergent Biodefense Operations Lansing LLC is a for-profit manufacturer. This contract was not set aside for any particular...
This firm fixed-price contract, valued at $762,812,695, was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company. The contract is for the development of medical countermeasures (MCM) that can be deployed in the event of a filovirus outbreak, which is a crucial component of the U.S. government's outbreak response...
This federal contract award, valued at $24,538,976.00, was issued by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services to Baxter Healthcare Corporation, doing business as Baxter Health Systems, for the procurement of pharmaceuticals. The contract is a definitive, firm-fixed price contract with an ultimate completion date of September 30, 2015. Baxter Healthcare Corporation, a manufacturer of medical devices, pharmaceuticals, and biotechnology products, serves as...
This is a $1,403,362,669.10 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company manufacturing medical countermeasures and pharmaceuticals. The contract, which has a period of performance through September 29, 2026, is for the development of filovirus treatments. Emergent has received over $1.3...
This is a $256,404,564 definitive contract awarded by the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Emergent Biosolutions Canada Inc. for the supply of Botulism Antitoxin Heptavalent (BAT) to treat botulism. The contract has a period of performance through March 31, 2029. This is a follow-on contract to a previous award and Emergent was selected as the sole source provider given its capability to manufacture the...
This is a federal contract award to Baxter Healthcare Corporation, doing business as Baxter Health Systems, by the Department of Health and Human Services Centers for Disease Control and Prevention in Pittsburgh. The 5-year Indefinite Delivery/Indefinite Quantity (IDIQ) contract, with a potential value of $613,860.52, is for the delivery of pharmaceuticals and medical/surgical supplies. The contract is not set aside for any specific business type. As the prime contractor, Baxter Health Systems...
This is a delivery order contract awarded by the Centers for Disease Control and Prevention (CDC) to Baxter Healthcare Corporation, doing business as Baxter Health Systems. The contract, with a ceiling value of $1,015,586.64, is for the exercise of Option Year 4 and has an ultimate completion date of September 30, 2017. The contract is a Firm Fixed Price arrangement and is not designated as a set-aside. As the prime contractor, Baxter Health Systems, a manufacturer of medical devices,...